Effects of orally administered pimobendan on platelet function in healthy adult cats
American Journal of Veterinary Research · 2023
DOI: 10.2460/ajvr.23.05.0103 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Veterinary Research, 2023. Verfasst von Rebecca Kennerly und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA. Hauptthemen laut MEDLINE: Pyridazines, Blood Platelets, Platelet Aggregation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
OBJECTIVE Several phosphodiesterase inhibitors have demonstrable antiplatelet actions when administered to human patients. Concentration-dependent inhibition of feline platelet aggregation by pimobendan has been previously demonstrated in vitro. However, there are no published reports characterizing the effect of oral pimobendan, administered at therapeutic doses, on platelet function in cats. This study aimed to evaluate the effect of orally administered pimobendan on platelet function in healthy adult cats. ANIMALS 6 healthy purpose-bred adult cats METHODS Cats were administered pimobendan orally at a dosage of 0.625 mg/cat (low-dose) twice daily for 1 week, followed by 1.25 mg/cat (high-dose) twice daily for 1 week. Venous blood sampling for platelet testing and plasma drug concentration occurred at baseline, 1 hour postdose on the eighth day of treatment with low-dose pimobendan, 1 hour postdose on the eighth day of treatment with high-dose pimobendan, and after a 1-week washout period. Platelet function was assessed by whole blood aggregometry and by use of a platelet function analyzer (PFA-100®). Friedman tests were used to compare platelet function parameters among the 4 sampling timepoints. RESULTS After 1 week of treatment, median (range) plasma pimobendan concentrations were 15.1 ng/mL (6.89–20.2 ng/mL) and 32.8 ng/mL (23.3–44.8 ng/mL) in cats receiving low-dose and high-dose pimobendan, respectively. No significant differences in PFA closure time or any aggregometry variable were found among the treatment conditions. CLINICAL RELEVANCE Pimobendan was not associated with measurable inhibition of platelet function when administered orally to healthy adult cats at 2 clinically relevant dosages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA.
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL.
Zitieren
APA
Kennerly, R., Coleman, A. E., Jasper, S. L., Arnold, R. D., & Brainard, B. M. (2023). Effects of orally administered pimobendan on platelet function in healthy adult cats. American Journal of Veterinary Research. https://doi.org/10.2460/ajvr.23.05.0103
Vancouver
Kennerly R, Coleman AE, Jasper SL, Arnold RD, Brainard BM. Effects of orally administered pimobendan on platelet function in healthy adult cats. American Journal of Veterinary Research. 2023. doi:10.2460/ajvr.23.05.0103
BibTeX
@article{Kennerly2023,
author = {Kennerly, Rebecca and Coleman, Amanda E and Jasper, Shanese L and Arnold, Robert D and Brainard, Benjamin M},
title = {Effects of orally administered pimobendan on platelet function in healthy adult cats},
journal = {American Journal of Veterinary Research},
year = {2023},
doi = {10.2460/ajvr.23.05.0103}
}
EUVIMED